These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 15374986)

  • 1. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
    Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.
    Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE
    Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
    Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
    Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.
    Gregson SJ; Howard PW; Gullick DR; Hamaguchi A; Corcoran KE; Brooks NA; Hartley JA; Jenkins TC; Patel S; Guille MJ; Thurston DE
    J Med Chem; 2004 Feb; 47(5):1161-74. PubMed ID: 14971896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
    Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
    J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.
    Guichard SM; Macpherson JS; Thurston DE; Jodrell DI
    Eur J Cancer; 2005 Aug; 41(12):1811-8. PubMed ID: 16046116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).
    Buhrow SA; Reid JM; Jia L; McGovern RM; Covey JM; Kobs DJ; Grossi IM; Ames MM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(1):56-62. PubMed ID: 16730244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
    Wade Calcutt M; Lee W; Puzanov I; Rothenberg ML; Hachey DL
    J Mass Spectrom; 2008 Jan; 43(1):42-52. PubMed ID: 17683023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
    Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
    BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.
    Rahman KM; Thompson AS; James CH; Narayanaswamy M; Thurston DE
    J Am Chem Soc; 2009 Sep; 131(38):13756-66. PubMed ID: 19725510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
    Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
    Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
    Suggitt M; Cooper PA; Shnyder SD; Bibby MC
    Int J Oncol; 2006 Dec; 29(6):1493-9. PubMed ID: 17088988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
    Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
    Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
    Hadjivassileva T; Thurston DE; Taylor PW
    J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
    Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
    Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.